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Summary Nitroimidazoles have been shown to be potent sensitisers of certain clinically active
chemotherapeutic agents. This process of chemopotentiation has been shown to be hypoxia-mediated. The
present studies evaluated whether increasing the level of hypoxia in the tumour tissue, by treatment with the
vasoactive agent hydralazine, could modify the chemosensitising ability of nitroheterocyclics. Administering
either misonidazole or RSU 1164 before, or hydralazine after, the chemotherapeutic agents melphalan,
cyclophosphamide or the nitrosourea CCNU, increased the extent of cell kill in both the KHT sarcoma and
RIF-I tumour. However, even greater enhancements could be achieved when hydralazine was used in
treatment protocols in which a nitroimidazole was combined with chemotherapy. For example, a 5.0 mg kg-'
dose of hydralazine given 30 min after melphalan, or a 2.5 mmol kg-' dose of misonidazole administered
30 min before melphalan, increased, compared to melphalan alone, the resultant tumour cell kill by factors of
- 1.9 and - 1.3, respectively. By comparison, when hydralazine was given after the melphalan plus
misonidazole combination, treatment efficacy was enhanced - 3-fold compared to melphalan alone. Yet in
contrast to the results of the tumour response studies, the inclusion of hydralazine did not increase the bone
marrow toxicity associated with the chemotherapeutic agent when used alone or in conjunction with a
nitroimidazole. The results, therefore, imply that the addition of hydralazine to the chemotherapy, or
chemotherapy-sensitiser protocol, led to a therapeutic advantage.
Strong evidence exists to support the notion that certain
human malignancies fail curative radiation therapy because,
during treatment, a proportion of the neoplastic cell popula-
tion is receiving an inadequate supply of oxygen (Bush et al.,
1978; Coleman, 1988). Similarly, tumours containing regions
in which the blood supply is poor may also be resistant to
certain chemotherapeutic agents (Sartorelli, 1986; Siemann,
1984). In the past, approaches directed at overcoming the
potential problem of tumour hypoxia have focused primarily
on the development of methods aimed at improving tumour
oxygenation by increasing the quantity of oxygen delivered to
the tumour (Hirst, 1987; Siemann, 1987).
An alternative strategy for dealing with tumour hypoxia
has been the use of agents demonstrating greater bioreductive
activation by hypoxic than aerobic cells. The classic example
of such a compound is the quinone antibiotic mitomycin C
(Kennedy et al., 1980; Sartorelli, 1986). More recently, other
agents, some showing preferential hypoxic cell cytotoxicities
far greater than that of mitomycin C, have been developed.
The most interesting of these may be the nitroimidazole RSU
1069 (Adams & Stratford, 1986) and the benzotriazine-N-
oxide SR 4233 (Zeman et al., 1986). Unlike mitomycin C,
however, these newer agents proved extremely ineffective
against aerobic tumour cells (Adams & Stratford, 1986;
Zeman et al., 1986; Brown, 1987; Siemann, 1989). For this
reason it was subsequently suggested that to make them
therapeutically beneficial, these hypoxia-targeted agents
might have to be given under conditions where it was possi-
ble to increase artificially oxygen deficiencies in tumours
during treatment. A number of physiological manipulations,
typically modifications of oxygen transport or blood flow,
can reduce tumour oxygenation (Hirst, 1987; Siemann, 1987;
Chaplin, 1987; Stratford et al., 1987). Of these approaches,
the use of the vasoactive drug hydralazine has received par-
ticular attention because it has been shown that treatment
with this agent not only selectively reduces tumour blood
flow, but also significantly potentiates the cytotoxicity of
bioreductive agents like RSU 1069 and SR 4233 in solid
tumour models (Chaplin, 1987, 1988; Brown, 1987; Chaplin
& Acker, 1987; Stratford et al., 1987). Reductions in tumour
blood flow by hydralazine also have been reported to
Received 19 February 1990; and in revised form 25 April 1990.
enhance hyperthermic damage (Horsman et al., 1989) as well
as the antitumour effect of certain chemotherapeutic agents
(Stratford et al., 1987; Chaplin et al., 1989). In addition,
when applied after irradiation, hydralazine-induced tumour
hypoxia can enhance the radiosensitising efficacy of the nit-
roheterocyclics, misonidazole and RSU 1069 (Chaplin, 1987,
1988; Stratford et al., 1987) but not that of etanidazole
(Stratford et al., 1987). Since nitroimidazoles can also
effectively augment the tumoricidal effects of certain bifunc-
tional alkylating agents both in vitro and in vivo (Brown,
1982; McNally, 1982; Siemann, 1982, 1984) and the expres-
sion of this chemosensitisation is hypoxia-mediated, the pre-
sent investigations were undertaken to determine whether
increasing the degree of tumour hypoxia by treatment with
hydralazine would enhance the chemosensitising activity of
nitroimidazoles.
Materials and methods
Animals and tumour models
All experiments were performed using either the KHT sar-
coma (Kallman et al., 1967) or the RIF-I tumour (Twen-
tyman et al., 1980). These tumours were carried in 8-14
week-old female C3H/HeJ mice obtained from Jackson
Laboratories, Bar Harbor, Maine. KHT cells were prepared
from solid tumours by mechanical dissociation (Thomson &
Rauth, 1974) and passaged in vivo every 2 weeks. RIF-I
tumour cells were maintained and passaged alternatively in
vitro and in vivo as described by Twentyman et al. (1980).
With both cell lines, solid tumours were initiated by
inoculating 2 x i0 cells i.m. into the hind limb. After the
tumours had grown to 0.2-0.3 g, the mice were allocated to
various groups and treated or kept as controls.
Drug treatments
Misonidazole and RSU 1164 were dissolved in phosphate-
buffered saline at concentrations of 20 and 24 mg ml-'
respectively. CCNU was initially dissolved in absolute
ethanol and then, immediately before injection, was further
diluted, with a 0.3% solution of hydroxypropyl methyl-
cellulose in saline, to yield a final concentration of
1.0 mgml'. Cyclophosphamide was dissolved in saline to
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yield a final concentration of 10mgml'. Melphalan was
dissolved in acid alcohol and subsequently diluted with saline
to a concentration of 1.0 mg ml ' just before injection. Hyd-
ralazine was prepared at 0.5 mg per ml of saline. All drugs
were administered intraperitoneally according to animal
weight. lo-l
Measurement oftumour response
Clonogenic cell survival Response of KHT sarcomas to sin-
gle agent or combination therapies was assessed using an in
vivo to in vitro tumour excision assay. Single cell suspensions
were prepared from tumours 24 h after drug treatment using
a combination mechanical and enzymatic (protease IX) dis-
sociation procedure. The tumours were finely minced and
then transferred to enzyme preparations (0.1% protease IX;
35 ml enzyme solution), which were incubated for 1 h with
constant agitation at 37C. The cells were then counted in a
haemocytometer and various dilutions were prepared. The
cells were mixed with 104 lethally irradiated tumour cells in
0.2% agar containing alpha-minimum essential medium sup-
plemented with 10% fetal calf serum and plated into 24-well
multiwell dishes. In about 2 weeks the surviving cells formed
colonies which were counted with the aid of a dissecting
microscope.
Tumour growth delay To assess the response of RIF-1
tumours, following treatment, the size of each tumour-
bearing leg was measured by passing it through a plastic rod
with holes of increasing diameter. The size of the smallest
hole through which the tumour-bearing leg would pass was
recorded. This size was converted to tumour weight using a
calibration curve (Siemann & Sutherland, 1980). The number
of days for each tumour to grow to 5 times the starting
weight was then determined. The median time for the
tumours of each group of mice to reach this endpoint was
calculated and plotted against dose. Confidence intervals
about the median were calculated using non-parametric
statistics (Noether, 1971).
Normal tissue toxicity
Toxicity of the single, or combined, modality treatments was
evaluated by measuring bone marrow stem cell survival using
modifications of the CFU-GM assay, as has been previously
described (Siemann & Allalunis-Turner, 1988). Briefly, mar-
row was flushed from the femurs of treated and untreated
mice and the nucleated cells were counted using a Coulter
Counter Channel Analyzer. Appropriate dilutions were made
and plated into 24-well multiwell dishes in 0.3% agar con-
taining alpha-minimum essential medium supplemented with
20% fetal calf serum, 10% bovine serum albumin and 10%
giant tumour cell colony stimulating factor. The resulting
colonies were counted 7 days later using an inverted micro-
scope.
Results
Previous investigations have shown that administering the
vasoactive drug hydralazine after melphalan treatment can
enhance the antitumour efficacy of this chemotherapeutic
agent (Stratford et al., 1987, 1988; Chaplin et al., 1989).
Consequently, this was the first chemotherapeutic agent
evaluated in the present studies. In concert with previous
observations, the results of Figure 1 show that when KHT
sarcoma-bearing mice were given hydralazine 15 to 30min
after a 5.0 mg kg-' dose of melphalan, the resultant tumour
cell kill was substantially enhanced (-10-fold). Also illus-
trated is the effect of pre-treating mice with a 2.5 mmol kg-'
(0.5 mg kg-') dose of misonidazole on the cytotoxic efficiency
of this dose of melphalan. Although the sensitiser increased
tumour cell kill due to the chemotherapeutic agent only
-2-3-fold, when hydralazine was administered at various
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Figure 1 Survival of KHT cells from tumours treated with a
5.0mgkg-' dose of melphalan either alone (open symbols) or
with a 2.5 mmol kg-' dose of misonidazole (closed symbols) at
various times before a 5.0 mg kg-' dose of hydralazine. The
sensitiser preceded the chemotherapeutic agent by 30 min. Data
are the mean ± S.E. of 3-6 experiments.
times after the melphalan-misonidazole combination, the
resultant cell survival was further reduced by a factor of
-50.
On the basis of the timing experiments illustrated in Figure
1, complete dose response studies, in which hydralazine was
given 30 min after a range of melphalan doses administered
either alone, or in combination with misonidazole, were per-
formed (Figure 2). At the doses used, neither hydralazine,
nor misonidazole, was directly cytotoxic alone. However, the
combination of 2.5 mmol kg-' misonidazole and 5.0 mg kg-l
hydralazine did reduce tumour cell survival to 0.7. In addi-
tion, both the sensitiser and hydralazine treatments poten-
tiated the action of melphalan, although the extent of the
enhancement of this particular chemotherapeutic agent was
far greater for hydralazine than misonidazole. For example,
enhancement ratios (ERs), defined as the ratio of the slopes
of the melphalan alone and melphalan plus misonidazole or
hydralazine cell survival curves, were calculated to be 1.3 and
1.9, respectively. An even larger antitumour effect (ER -3.0)
could be achieved when hydralazine was administered after
the misonidazole-melphalan combination.
Figure 3 shows the effect of administering misonidazole, or
hydralazine, in combination with the nitrosourea CCNU.
Both agents, when used alone with a range of doses of
CCNU, resulted in an ER of -1.5. The data in this figure
further indicate that when KHT sarcoma-bearing mice were
treated with a combination of CCNU plus misonidazole
before hydralazine, the extent of tumour cell killing was
increased compared to that seen for CCNU + misonidazole,
or CCNU + hydralazine alone. The observed ER for the
three agent combination was -2.5. A similar enhancement in
CCNU activity resulted when KHT sarcoma-bearing mice
were given hydralazine 30 min after a CCNU-RSU 1164
(2.0 mmol kg-') combination (Figure 4).
The clonogenic cell survival of KHT sarcoma cells treated
in vivo with cyclophosphamide ± misonidazole ± hydralazine
is illustrated in Figure 5. The enhancement of the antitumour
activity of cyclophosphamide was essentially the same (ER
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Figure 2 Clonogenic cell survival in KHT sarcomas treated with
melphalan (0), melphalan plus misonidazole (0), melphalan
plus hydralazine (0) or all 3 agents combined (-). Misonidazole
(2.5 mmol kg-') and hydralazine (5.0 mg kg-1) were given 30 min
before, or after, chemotherapy, respectively. Data points are the
mean ± S.E. of 3-5 experiments or (points without error bars)
the average. values of 1 or 2 experiments with each point
representing 2-4 tumours.
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Figure 4 The effect of hydralazine (5.0mg kg-') given 30 min
after CCNU plus RSU 1164 (U) on KHT sarcoma cell survival.
RSU 1164 (2.0 mmol kg-') was administered 30 min before
CCNU. Tumour response to CCNU (0) or CCNU plus RSU
1164 (0) in the absence of hydralazine are shown for com-
parison.
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Figure 3 Tumour cell kill in KHT sarcomas treated with CCNU
(0), CCNU plus misonidazole (0) or hydralazine (0) or CCNU
plus both agents (O). Doses and timings were as in Figure 2.
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Figure 5 Clonogenic cell survival in KHT sarcomlas treated with
cyclophosphamide alone (0), cyclophosphamide plus misonida-
zole (-) or hydralazine (0), or cyclophosphamide plus misoni-
dazole and hydralazine (U). Doses and timings were as in Figure
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- 1.3) when this chemotherapeutic agent was combined with
either misonidazole or hydralazine (solid circles vs open
squares). However, when all three agents were administered,
the resultant enhancement ratio increased to -1.6. For com-
parison, the response of RIF-1 tumours to cyclophospha-
mide ± misonidazole ± hydralazine was also evaluated using
a tumour growth delay assay (Figure 6). The results indicate
that, just as was seen in the survival studies performed in
KHT sarcomas (Figure 5), both misonidazole and hydrala-
zine improved the response of RIF-I tumours to cyclophos-
phamide (solid circles and open squares vs open circles).
Also, post-cyclophosphamide treatment with hydralazine
enhanced the degree of sensitiser chemopotentiation (solid
squares vs solid circles). Using tumour growth delay as the
endpoint, the administration of hydralazine after the miso-
nidazole-cyclophosphamide combination increased the ER
from -1.4 to -2.0.
To determine whether the inclusion of hydralazine in a
chemosensitisation protocol could lead to a therapeutic bene-
fit, bone marrow toxicity due to melphalan alone, or melpha-
lan in combination with the sensitiser or vasoactive drug, was
assessed. The survival of CFU-GM in tumour-bearing mice
24 h after treatment with these combinations is illustrated in
Figure 7. The data show that increasing doses of melphalan
lead to decreasing CFU-GM survival (open circles). How-
ever, this melphalan-induced bone marrow toxicity was not
enhanced by misonidazole (solid circles), hydralazine (open
squares) or the two agents used in combination (solid
squares).
Discussn
Tumours often contain poorly developed vasculatures which
may lead to heterogeneous oxygen distributions and the
development of acutely and chronically hypoxic tissue
regions. The presence of such hypoxic tumour cell sub-
populations can limit the success of tumour eradication by
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Figure 6 Regrowth delay in RIF-I tumours treated with cyclo-
phosphamide either alone (0), in combination with misonidazole
(-) or hydralazine (0) or both agents (U). The sensitiser and
hydralazine exposures and timings were as in Figure 2. Data
show in the median tumour response ± 95% confidence limits in
groups of 7-9 mice.
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Figure 7 Bone marrow stem cell survival (CFU-GM) determined
in mice treated with melphalan alone (0), melphalan plus misonidazole (@) or hydralazine (0), or melphalan plus misoni-
dazole and hydralazine (U). Treatments and time schedules used
were as in Figure 2.
radiotherapy or anticancer drugs. To overcome inadequacies in blood supply, the use ofvasoactive drugs to increase blood
flow in tumours has been considered. It has, however,
become clear that, rather than improving oxygen availability,
most vasoactive agents actually decrease tumour blood flow
and oxygenation (Kruuv et al., 1967). Rather than viewing
the induced tumour hypoxia as a hindrance, Chaplin and
colleagues (Chaplin, 1987, 1988; Chaplin & Acker, 1987)
recognised the potential therapeutic advantage of combining
a vasoactive agent with a bioreductive drug. Since their initial
investigations, improved tumour responses resulting from
such a combined modality approach have now also been
reported from a number of other laboratories (Brown, 1987;
Stratford et al., 1987). The use of post-treatment hydralazine
exposure has not, however, been restricted to the combina-
tion with bioreductive drugs. In addition, this treatment
strategy has been shown to yield effective enhancement of
selected chemotherapeutic agents and hyperthermia (Chaplin,
1987; Stratford et al., 1988). Interestingly, Horsman et al.
(1989) have used pretreatment hydralazine to demonstrate
enhancement of hyperthermia.
The aim of the present studies was to determine whether
increasing the degree of tumour hypoxia by treatment with
hydralazine would enhance the chemosensitising activity of
nitroimidazoles. Chemosensitisation studies have now been
reported by many investigators and it has been ascertained
that nitroimidazoles can effectively augment the tumoricidal
effects of bifunctional alkylating agents and certain nitro-
soureas both in vitro and in vivo (Brown, 1982; McNally,
1982; Siemann, 1982, 1984). Further, the majority of these
investigations implicate hypoxia as a requirement for the
expression of chemosensitisation (Siemann, 1984; Siemann &
Mulcahy, 1986). Consequently, it was anticipated that in-
creasing the level of tumour hypoxia by treatment with hyd-
ralazine might enhance the degree of nitroimidazole-induced
chemosensitisation. In our initial experiments hydralazine
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was administered at various times after melphalan treatment
and the time course of enhanced tumour cell killing was
monitored (Figure 1). The data indicate that administering
hydralazine 15 to 30 min post-chemotherapy was optimum
for this effect. The results further show that the potentiation
of melphalan efficacy by misonidazole is also enhanced by
post-treatment hydralazine exposure and that the modifi-
cation of this potentiation follows similar time kinetics to
those seen for melphalan plus hydralazine (solid vs open
squares). Although tumour blood flow measurements were
not made, experiments in which the tumours of mice were
irradiated 15 to 30 min after treatment with hydralazine,
demonstrated surviving fractions indistinguishable from those
obtained in tumours which were clamped at the time of
irradiation, or in tumours which were irradiated in dead mice
(data not shown). These findings imply that in the present
experiments, treatment with hydralazine led to tumour
hypoxic fractions near or at, 100%.
On the basis of studies like those shown in Figure 1, the
combination of alkylating chemotherapy and post-treatment
hydralazine exposure was evaluated in clonogenic cell sur-
vival studies using the KHT sarcoma (Figures 2-5). For the
3 chemotherapeutic agents tested, the inclusion of hydra-
lazine resulted in increased tumour chemosensitivity corres-
ponding to ERs of 1.3, 1.5 and 1.9 for cyclophosphamide,
CCNU and melphalan respectively. A comparable ER (1.4)
was obtained when RIF-1 tumours were treated with cyclo-
phosphamide plus hydralazine and assayed by tumour
growth delay (Figure 6).
Enhanced tumour responses resulting from post-chemo-
therapy administration of the vasoactive agent hydralazine as
described above could be the consequence of increased trap-
ping of the chemotherapeutic agent in the tumour tissue. In
addition, increased tissue hypoxia following hydralazine
exposure will result in a more acidic environment in the
tumour owing to increased anaerobic cell metabolism. Such a
change in the environmental pH also could play a significant
role in the observed enhanced treatment efficacy particularly
for the agent melphalan. This is because a number of in vitro
investigations have demonstrated increased tumour cell sen-
sitivity to melphalan under hypoxic and acidic treatment
conditions (Rotin et al., 1986; Chaplin et al., 1989; Siemann
et al., 1990). Post-irradiation modification of tumour blood
flow has also been shown to increase the effectiveness of
misonidazole and RSU 1069 as radiosensitisers (Chaplin,
1988; Stratford et al., 1987). Since nitroheterocyclics are
efficient sensitisers of certain alkylating agents for treatments
given under hypoxic conditions (Siemann & Mulcahy, 1986),
the present studies assessed whether treatment with hydra-
lazine could enhance nitroimidazole-mediated chemopotentia-
tion in vivo. The results demonstrate that this is indeed the
case. As has been previously described, combining misoni-
dazole or RSU 1164 with cyclophosphamide, melphalan or
CCNU resulted in enhanced tumour responses (Figures 2-6).
However these ERs could be significantly increased when a
5.0 mg kg-' dose of hydralazine was administered 30 min
after the drug-sensitiser combination (Figures 2-6). Since
misonidazole itself can reduce blood flow (Murray & Rand-
hawa, 1988), it is conceivable that the nitroimidazole-hydra-
lazine combination produced a greater reduction in tumour
blood flow than was achieved by hydralazine alone, and thus
led to a greater chemotherapeutic agent response. It is more
likely, however, that increasing the degree oftumour hypoxia
by treatment with hydralazine resulted in enhanced
chemosensitising activity of the nitroimidazoles.
The present findings indicate that hydralazine administra-
tion post-chemotherapy could enhance both the efficacy of
the chemotherapeutic agent and the degree ofchemosensitisa-
tion achievable by nitroimidazoles. Although these studies
were conducted using a hydralazine dose of 5.0 mg kg-',
recent experiments (Table I) have indicated that substantially
lower doses of this vasodilator could also be effective. The
enhancement in tumour cell kill did decline with reduced
hydralazine doses. However, a comparison of the data in
Figure 1 and Table I shows that hydralazine doses of 1.0 and
2.5 mg kg-' were sufficient to achieve a considerable increase
in the efficacy of the chemotherapy.
From a therapeutic point of view, it is perhaps most
critical that the observed enhancements in tumour response
were not associated with similar increases in normal tissue
toxicity. Bone marrow stem cell toxicity was related solely to
the melphalan doses used and was not increased for the 2 to
3 agent combinations (Figure 7). Thus on the basis of a
therapeutic gain, the present findings suggest a real advant-
age in using hydralazine to potentiate the activity of both the
chemotherapeutic agent or the chemotherapeutic agent-nitro-
imidazole combination. The results imply that the use of a
vasodilator like hydralazine may provide an alternative ap-
proach to improving therapy. Nevertheless, future studies
will need to establish whether hydralazine therapy is ap-
plicable to human tumours in a clinical setting.
Table I Effect of hydralazine (1.0 or 2.5 mgkg-') given 30 min
after melphalan (5.0 mg kg-') or melphalan (5.0 mg kg-') plus
misonidazole (2.5 mmol kg-') on tumour cell killing in the KHT
sarcoma
Treatment Surviving Fractiona
Melphalan alone 9.2 _ 4.5 x 10-2
Melphalan + hydralazine (1.0 mg kg-') 1.0 ± 0.3 x 10-2
Melphalan + misonidazole + hydralazine 2.0 _ 0.8 x 10-3
(1.0mg kg-')
Melphalan + hydralazine (2.5 mg kg-') 8.2 ± 2.0 x 10-3
Melphalan + misonidazole + hydralazine 8.3 ± 2.2 x 10-4
(2.5 mgkg-')
aValues shown are the mean ± S.E. of 4-6 determinations.
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